Augmentation with Amisulpride for Schizophrenic Patients Non-Responsive to Risperidone Monotherapy

Abstract

Introduction: The combination of antipsychotic drugs is a therapeutic resource in clinical practice. This study aimed to evaluate the efficacy and security of adding amisulpride in patients who at least partially responded to risperidone.

Methods: A 3-month, open, observational study was undertaken to evaluate the effectiveness of adding amisulpride in subjects who scored at least 25 on the brief psychiatric rating scale (BPRS) after risperidone monotherapy. Patients were evaluated with BPRS, the Clinical Global Impressions Severity of Illness scale (CGI-S) and the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale (UKU) at baseline, 1 and 3 months.

Results: Coadjuvant treatment with amisulpride achieves a statistically significant improvement in mental status over a period of 3 months when measured with BPRS, CGI and UKU scales. The response rate was 70 (45%) in the oral risperidone and 74 (28%) in the parenteral risperidone groups.

Discussion: The addition of amisulpride could lead to an improvement in schizophrenia symptoms in patients that do not, or only partially, respond to risperidone. Further research is required into alternative therapies for poor responders.

Key words

risperidone - amisulpride - augmentation - schizophrenia

• References

• 1 Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010; 23: 103-111
• 2 Barbui C, Signoretti A, Mulè S et al. Does the addition of a second antipsychotic drug improve clozapine treatment?. Schizophr Bull 2009; 35: 458-468
• 3 National Association of State Mental Health Program Directors, Medical Directors Council and State Medicaid Directors . NASMHPD Medical Directors Technical Report on Psychiatric Polypharmacy. Alexandria: NASMHPD Research Institute, Inc; 2001
• 4 Lerma-Carrillo I, Molina JD, Gonzalez-Parra S et al. Rational antipsychotic polypharmacy. Can J Clin Pharmacol 2008; 15: e420-e421
• 5 Leucht S. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2004; 7 (Supp. 1) S15-S20
• 6 Kissling W. Compliance, quality management and standards in the treatment of Schizophrenia. Neuropsichobiology 1997; 35: 70-72
• 7 Jossiasen RC, Joseph A, Kohegyi E et al. Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162: 130-136
• 8 Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI et al. A double blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety. J Clin Psychiatry 2005; 66: 63-72
• 9 Honer WG, Thornton AE, Chen EY et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354: 472-482
• 10 Freudenreich O, Henderson DC, Walsh JP et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial. Schizophr Res 2007; 92: 90-94
• 11 Zink M, Kuwilsky A, Krumm B et al. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol 2009; 23: 305-331
• 12 Hatta K, Otachi T, Sudo Y et al. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. Psychiatry Res 2012; 198: 194-201
• 13 Genc Y, Taner E, Candansayar S. Comparison of clozapine amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized study. Adv Ther 2007; 24: 1-13
• 14 Kotler M, Strous RD, Reznik I et al. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: Evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 2004; 19: 23-26
• 15 Assion HJ, Reinbold H, Lemanski S et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008; 41: 24-32
• 16 Koreen AR, Lieberman JA, Kronig M et al. Cross-tapering clozapine and risperidone. Am J Psychiatry 1995; 152: 1690
• 17 McCarthy RH, Terkelsen KG. Risperidone augmentation of clozapine. Pharmacopsychiatry 1995; 28: 61-63
• 18 Tyson SC, Devane CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 1995; 152: 1401-1402
• 19 Chong SA, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: Two case reports. J Clin Psychopharmacol 1997; 17: 68-69
• 20 Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996; 57: 395-397
• 21 Godleski LS, Sernyak MJ. Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 1996; 153: 735-736
• 22 Chong SA, Tan CH, Lee HS. Hoarding and clozapine-risperidone combination. Can J Psychiatry 1996; 41: 315-316
• 23 Patel JK, Salzman C, Green AI et al. Chronic schizophrenia: Response to clozapine, risperidone, and paroxetine. Am J Psychiatry 1997; 154: 543-546
• 24 John V, Rapp M, Pies R. Aggression, agitation, and mania with olanzapine. Can J Psychiatry 1998; 43: 1054
• 25 Mantonakis I, Kattan K, Zervas IM. Risperidone augmentation of clozapine and olanzapine for refractory schizophrenia. Eur Neuropsychopharmacol 1998; 8: 233
• 26 Zervas IM, Kattan K, Mantonakis I. Risperidone-clozapine combination for refractory schizophrenia. Eur Neuropsychopharmacol 1998; 8: 37
• 27 Bork JA, Rogers T, Wedlund PJ et al. A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3 A. J Clin Psychiatry 1999; 60: 469-476
• 28 Morera AL, Barreiro P, Cano-Munoz JL. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr Scand 1999; 99: 305-306 discussion 306–307
• 29 Adesanya A, Pantelis C. Adjunctive risperidone treatment in patients with ‘clozapine resistant schizophrenia’. Aust N Z J Psychiatry 2000; 34: 533-534
• 30 Lerner V, Chudakova B, Kravets S et al. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: A preliminary case series report. Clin Neuropharmacol 2000; 23: 284-286
• 31 Margolese HC, Kolivakis TT, Turnier L et al. Clinical improvement with quetiapine augmentation of combination atypical antipsychotic pharmacotherapy in treatment resistant schizophrenia and schizoaffective disorder. Presented at 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico Dec. 10-14 2000; 188
• 32 Raskin S, Durst R, Katz G et al. Olanzapine and sulpride: preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J Clin Psychopharmacol 2000; 20: 500-503
• 33 Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001; 20: 215-219
• 34 Chue P, Welch R, Snaterse M. Combination risperidone and quetiapine therapy in refractory schizophrenia. Can J Psychiatry 2001; 46: 86-87
• 35 De Groot IW, Heck AH, van Harten PN. Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J Clin Psychiatry 2001; 62: 129-130
• 36 Henderson DC, Goff DC, Connolly CE et al. Risperidone added to clozapine: Impact on serum prolactin levels. J Clin Psychiatry 2001; 62: 605-608
• 37 Raju Kumar R, Khanna S. Clozapine-risperidone combination in treatment-resistant schizophrenia. Aust N Z J Psychiatry 2001; 35: 543
• 38 Seger A, Lamberti JS. Priapism associated with polypharmacy. J Clin Psychiatry 2001; 62: 128
• 39 Taylor CG, Flynn SW, Altman S et al. An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 2001; 48: 155-158
• 40 Beauchemin MA, Millaud F, Nguyen KA. A case of neuroleptic malignant syndrome with clozapine and risperidone. Can J Psychiatry 2002; 47: 886
• 41 Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS et al. Toxic interaction between risperidone and clozapine: A case report. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 407-409
• 42 Potkin SG, Thyrum PT, Alva G et al. The safety and pharmacokinetics of quetiapine when co-administered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002; 22: 121-130
• 43 Procyshyn RM, Tse G, Sin O et al. Concomitant clozapine reduces smoking in patients treated with risperidone. Eur Neuropsychopharmacol 2002; 12: 77-80
• 44 Raaska K, Raitasuo V, Neuvonen PJ. Therapeutic drug monitoring data: Risperidone does not increase serum clozapine concentration. Eur J Clin Pharmacol 2002; 58: 587-591
• 45 Senechal A, Landry P, Deschamps R et al. Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs. Encephale 2002; 28: 567-569
• 46 Bozikas VP, Deseri C, Pitsavas S et al. Antiaggressive action of combined risperidone and quetiapine in a patient with schizophrenia. Can J Psychiatry 2003; 48: 426-442
• 47 Nelson MW, Reynolds RR, Kelly DL et al. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone. Clin Neuropharmacol 2003; 26: 297-298
• 48 Ramaswamy S, Vijay D, William M et al. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 2004; 19: 45-48
• 49 Suzuki T, Uchida H, Watanabe K et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol 2008; 23: 455-463
• 50 Suzuki T, Uchida H, Watanabe K et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum. Psychopharmacol Clin Exp 2008; 23: 455-463
• 51 Kim SE, Jung DC, Ahn YM et al. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. J Psychopharmacol 2010; 24: 981-998
• 52 Raskin S, Katz G, Zislin Z et al. Clozapine and risperidone: Combination/augmentation treatment of refractory schizophrenia: A preliminary observation. Acta Psychiatr Scand 2000; 101: 334-336
• 53 Pedrosa GF, Schneider C, Grohmann R et al. Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy. Nervenarzt 2001; 72: 729-733
• 54 Jones GH. ‘Clozapine effect’ without the blood tests?. Prog Neurol Psychiatry 2002; 6: 32
• 55 O’Shea M, Sazhin V, Collins A. Ventricular ectopics during crossover of atypical antipsychotics. Aust N Z J Psychiatry 2003; 37: 773-774
• 56 Agelink MW, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 2004; 161: 924-925
• 57 Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004; 19: 56-58
• 58 Zink M, Knopf U, Henn FA et al. Combination of clozapine and amisulpride in treatment-resistant schizophrenia: Case reports and review of the literature. Pharmacopsychiatry 2004; 37: 26-31
• 59 Kämpf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride: A promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005; 38: 39-40
• 60 Lerner V, Bergman J, Borokhov A et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005; 28: 66-71
• 61 Pani L, Villagrán JM, Kontaxakis VP et al. Practical issues with amisulpride in the management of patients with schizophrenia. Clin Drug Investig 2008; 28: 465-477
• 62 Chiu HW, Ku YC, Li TC et al. Amisulpride augmentation of clozapine in refractory schizophrenia. J Neuropsychiatry Clin Neurosci 2011; 23: E15
• 63 Molina JD, Toledo-Romero F, López-Rodríguez E et al. Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine. Pharmacopsychiatry 2011; 44: 142-151
• 64 Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 2012; 22: 165-218
• 65 Hotham JE, Simpson PJ, Brooman-White RS et al. Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. CNS Spectrums, available on CJO2013
• 66 Lerner V, Libov I, Kotler M et al. Combination of “atypical” antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 89-98
• 67 Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799-812
• 68 Guy W. ECDEU Assessment Manual for Psychopharmacology – Revised (DHEW Publ No ADM 76-338). Rockville: Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976: 218-222
• 69 Lingjaerde O, Ahlfors UG, Bech P et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scan Suppl 1987; 76: 1-10
• 70 Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 2008; 8: 1-14
• 71 Correll CU, Rummel-Kluge C, Cirves C et al. Antipsychotic combinations vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35: 443-457
• 72 Correll CU, Malhotra AK, Kaushik S et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003; 160: 2063-2065. erratum in Am J Psychiatry 2005; 162: 1774